Detalles de la búsqueda
1.
Prognostic value of indoleamine 2,3 dioxygenase in patients with higher-risk myelodysplastic syndromes treated with azacytidine.
Br J Haematol
; 190(3): 361-370, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32350858
2.
Inhibition of PLK1 by capped-dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis.
Eur J Haematol
; 104(2): 125-137, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31758597
3.
Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes.
Genes Chromosomes Cancer
; 58(10): 689-697, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30994215
4.
Serum Vitamin D Levels in Patients with Myelodysplastic Syndromes: A Retrospective Single-Center Analysis.
Acta Haematol
; 141(4): 225-231, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30965326
5.
Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia.
Haematologica
; 101(8): 932-40, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27175029
6.
Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group.
Genes Chromosomes Cancer
; 54(12): 809-17, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26355708
7.
Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group.
Haematologica
; 100(2): 205-13, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25344522
8.
Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.
Haematologica
; 99(10): e179-81, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24972774
9.
A limited number of 5-azacitidine cycles can be effective treatment in MDS.
Ann Hematol
; 88(3): 213-9, 2009 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-18696067
10.
Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose.
Exp Hematol Oncol
; 8: 9, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31016067
11.
Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature.
Oncotarget
; 9(45): 27882-27894, 2018 Jun 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29963245
12.
Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile.
Oncotarget
; 9(25): 17270-17281, 2018 Apr 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29707107
13.
Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesis.
Blood Adv
; 2(23): 3447-3461, 2018 12 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30518537
14.
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
J Clin Oncol
; 35(14): 1591-1597, 2017 May 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28350519
15.
Induction of apoptosis by Legionella pneumophila in mammalian cells requires the mitochondrial pathway for caspase activation.
Microbes Infect
; 8(3): 662-9, 2006 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-16476563
16.
Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study.
Leuk Res
; 37(8): 900-6, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23623559
Resultados
1 -
16
de 16
1
Próxima >
>>